New Zealand markets closed

Roche Holding AG (RHHVF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
395.13-1.12 (-0.28%)
At close: 03:18PM EST
Full screen
Trade prices are not sourced from all markets
Previous close396.25
Open405.00
Bid0.00 x 0
Ask0.00 x 0
Day's range389.25 - 405.00
52-week range308.57 - 411.44
Volume588
Avg. volume3,948
Market cap340.101B
Beta (5Y monthly)0.27
PE ratio (TTM)22.35
EPS (TTM)17.68
Earnings dateN/A
Forward dividend & yield9.78 (2.47%)
Ex-dividend date18 Mar 2021
1y target estN/A
  • GlobeNewswire

    Roche completed the repurchase of Roche shares from Novartis

    Basel, 6 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it completed the repurchase of Roche shares that had been held by Novartis. On 4 November 2021, Roche and Novartis had announced this repurchase. The Extraordinary General Meeting of Roche Holding Ltd passed the resolutions required for the repurchase and the capital reduction on 26 November 2021. In accordance with the respective resolution of the Extraordinary General Meeting of 26 November 2021, the 53,309,000 sh

  • GlobeNewswire

    CHMP recommends EU approval of Actemra/RoActemra to treat patients with severe COVID-19

    Actemra/RoActemra reduced the risk of death in patients with severe COVID-19, as evidenced by a review of four phase III studiesThe European Commission is expected to make a final decision regarding approval in the near future Basel, 06 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended extending the marketing authorisation for Actemra®/RoActemra® (tocilizumab) to incl

  • GlobeNewswire

    Roche to launch SARS-CoV-2 & Flu A/B Rapid Antigen Test in countries accepting the CE Mark to enable rapid differentiation of viral respiratory infections

    The combination rapid antigen test quickly differentiates between SARS-CoV-2 and influenza viruses A and B infections, with results ready in less than 30 minutes, allowing informed decisions on patient and pandemic management decisionsAffordable and small, instrument-free testing kit enables convenient use for healthcare professionals at different point of care locations and in resource-limited settingsThe test works seamlessly with NAVIFY® Pass, Roche’s digital solution that allows individuals